Zhejiang Hisoar Chuannan Pharma Co
Zhejiang Hisoar Chuannan Pharma Co., Ltd., commonly referred to as Hisoar Pharma, is a prominent player in the pharmaceutical industry, headquartered in China. Established in 2001, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, particularly in the fields of antibiotics and anti-infectives. With a strong operational presence across various regions in China and beyond, Hisoar Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include a diverse range of active pharmaceutical ingredients (APIs) and finished dosage forms, distinguished by their efficacy and safety profiles. Hisoar Pharma has achieved notable market recognition, positioning itself as a trusted supplier in both domestic and international markets, underscoring its dedication to advancing healthcare solutions.
DitchCarbon Score
How does Zhejiang Hisoar Chuannan Pharma Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zhejiang Hisoar Chuannan Pharma Co's score of 5 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zhejiang Hisoar Chuannan Pharma Co's reported carbon emissions
Zhejiang Hisoar Chuannan Pharma Co., Ltd., headquartered in China, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets for the future. The firm is committed to reducing its absolute Scope 1 and Scope 2 greenhouse gas emissions by approximately 50.4% by the year 2032, using 2022 as the baseline year. Additionally, it aims to achieve a 30% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit temperature rise to 1.5°C. Zhejiang Hisoar Chuannan Pharma's proactive approach to climate action reflects its commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company has not yet committed to a net-zero target but is actively working towards substantial emissions reductions in the coming years.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zhejiang Hisoar Chuannan Pharma Co is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
